Goldfinch Diagnostics Inc focuses on the development of diagnostics tests based on genetic engineering techniques to help address infectious disease problems, particularly in Latin American countries. GDI presently develops a serologic assay based on the use of a hybrid recombinant Trypanosoma cruzi protein as target antigen in an ELISA format. Goldfinch is focused to the basic developmental work of the chimeric T. cruzi proteins, followed by their being licensed to Abbott Laboratories
